How does asparaginase kill leukaemia cells?

It depletes the blood of the amino acid asparagine. Leukaemic lymphoblasts cannot make their own asparagine, so they run out of the building blocks for protein synthesis and die, while normal cells largely cope.

Is asparaginase a safe supplement or peptide I can take?

No. It is a prescription chemotherapy enzyme with serious risks including anaphylaxis, pancreatitis, and blood clots, and is only given under specialist oncology supervision. It is not a wellness or research peptide for personal use.

What are the most serious side effects?

Allergic/hypersensitivity reactions (including anaphylaxis), acute pancreatitis, venous thrombosis such as cerebral sinus thrombosis, hepatotoxicity, and metabolic effects like high blood sugar and high triglycerides.

How is native asparaginase different from pegaspargase?

Native E. coli asparaginase is short-acting and needs frequent dosing, whereas pegaspargase is a pegylated long-acting form that lasts longer per dose; pegaspargase has become the standard first-line asparaginase in many modern ALL protocols.

EMA-approved

Asparaginase — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Asparaginase is a peptide catalogued under Enzymes. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Asparaginase?

Asparaginase (native E. coli L-asparaginase) is an enzyme approved for decades as a core component of multi-agent chemotherapy for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma.

Evidence is high-level and clinical: its role is established across cooperative-group ALL protocols, though native E. coli formulations have been largely superseded in many markets by pegylated and recombinant products.

This is a regulator-approved oncology drug, not an investigational or wellness peptide.

How does Asparaginase work?

Asparaginase hydrolyses circulating L-asparagine (and some glutamine) into aspartic acid and ammonia, depleting the extracellular asparagine that leukaemic lymphoblasts cannot synthesise themselves.

Deprived of asparagine, the leukaemic cells cannot sustain protein synthesis and undergo apoptosis, while normal cells are relatively spared.

What does the research say about Asparaginase?

Asparaginase is an established backbone of curative multi-agent ALL regimens, and reviews describe asparagine depletion as central to leukaemic-cell kill. ^[1]
In a randomized paediatric trial, recombinant E. coli asparaginase achieved adequate serum asparaginase activity comparable to established asparaginase products. ^[2]
Structured toxicity-management guidance allows clinicians to keep patients on asparaginase, preserving its outcome benefit rather than dropping doses. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase — Pieters R et al., Cancer 2011. (Narrative review)
[2] Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group — van der Sluis IM et al., Pediatric Blood and Cancer 2018. (Randomized multicenter trial)
[3] Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia — Thu Huynh V et al., Clinical Journal of Oncology Nursing 2017. (Clinical review)
[4] Asparaginase-associated toxicity in children with acute lymphoblastic leukemia — Hijiya N et al., Leukemia and Lymphoma 2016. (Review)
[5] Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation — van der Sluis IM et al., Haematologica 2016. (Expert consensus recommendations)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Dosing is protocol-defined and physician-administered within oncology ALL regimens, given intramuscularly or intravenously in scheduled courses during induction, consolidation, and delayed-intensification phases.

This is context only, not clinical guidance; actual dose, formulation, and monitoring are set by the treating haemato-oncology team per cooperative-group protocol.

Side effects & safety profile

Asparaginase carries substantial, well-documented toxicity: hypersensitivity/allergic reactions (including anaphylaxis and clinically silent inactivation), acute pancreatitis, venous thromboembolism (notably cerebral sinus thrombosis), and hepatotoxicity.

It can also cause hyperglycaemia, hypertriglyceridaemia, and coagulopathy from reduced hepatic protein synthesis.

Toxicities require active monitoring, and severe pancreatitis or true anaphylaxis usually means permanent discontinuation of the specific formulation.

Stacking & combinations

Asparaginase is never used alone; it is one agent within multi-drug ALL chemotherapy alongside vincristine, corticosteroids, anthracyclines, and antimetabolites.

Finding Asparaginase vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is an enzyme used as part of multi-agent chemotherapy for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma, primarily in children but also in adults.

References

[1] L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase — Pieters R et al., Cancer 2011. PMID: 20824725. View sourceStudy: Narrative reviewReviews asparagine-depletion mechanism and the role of asparaginase products, including switching to Erwinia asparaginase after E. coli hypersensitivity.
[2] Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group — van der Sluis IM et al., Pediatric Blood and Cancer 2018. PMID: 29727043. View sourceStudy: Randomized multicenter trialRecombinant E. coli asparaginase achieved adequate serum asparaginase activity with an acceptable safety profile in newly diagnosed paediatric ALL.
[3] Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia — Thu Huynh V et al., Clinical Journal of Oncology Nursing 2017. PMID: 28945721. View sourceStudy: Clinical reviewSummarises identification and management of hypersensitivity, pancreatitis, thrombosis, hepatotoxicity, and hyperglycaemia during asparaginase therapy.
[4] Asparaginase-associated toxicity in children with acute lymphoblastic leukemia — Hijiya N et al., Leukemia and Lymphoma 2016. PMID: 26457414. View sourceStudy: ReviewCharacterises the major asparaginase toxicities in children, including thrombosis, pancreatitis, allergy, and hepatic dysfunction, and their clinical impact.
[5] Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation — van der Sluis IM et al., Haematologica 2016. PMID: 26928249. View sourceStudy: Expert consensus recommendationsProvides consensus guidance on detecting clinical hypersensitivity and silent inactivation via asparaginase-activity monitoring and switching formulations.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.